Assessing the Effects of Levofloxacin Combined with Cefoperazone/Sulbactam for the Treatment of Ventilator-Associated Pneumonia
Abstract
Objective To evaluate the efficacy and safety of Levofloxacin combined with Cefoperazone/Sulbactam on the patients with ventilator-associated pneumonia(VAP).Methods The clinical effect of Levofloxacin combined with Cefoperazone/Sulbactam on ventilator-associated pneumonia in 58 paitiens with VAP were retrospectively analyzed.Results 26 patients(44.8%) were cured,18 patients(31.1%) were marked improved,and 14 patients(24.1%) were ineffective.The total clinical efficacy rate was 75.9%.55 strains of bacteria were isolated,and Gram-negative bacilli were dominant pathogens(78.2%).The bacterial clearance rate was 78.2%.The prevalence of adverse reaction was 5.1%.Conclusion Levofloxacin combined with Cefoperazone/Sulbactam is effective and safe for patients with VAP.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.